Avalo Therapeutics Inc (AVTX)

Over the past six months, Avalo Therapeutics' stock has experienced fluctuations. As of April 10, 2026, the share price was $13.66, a significant increase over the past year, but recently decreased by 3.87%. Key events impacting the stock include emphasis on the Phase 2 LOTUS trial for AVTX-009 and the company's cash runway. Avalo Therapeutics reported its 2025 financial results and business updates on March 23, 2026, highlighting upcoming Phase 2 LOTUS topline data expected in Q2 2026. The company's cash, cash equivalents, and short-term investments were $98.3 million as of December 31, 2025, expected to fund operations into 2028. Research and development expenses increased in 2025, driven by costs related to the Phase 2 LOTUS trial, leading to a net loss of $78.3 million in 2025 compared to $35.1 million in 2024. Technical signals in early March 2026 indicated a potential downward trend.

As a clinical-stage biotechnology company, Avalo Therapeutics, Inc.'s financial performance and stock valuation are more influenced by clinical trial progress, regulatory milestones, and financial results rather than seasonal consumer demand. However, there is some seasonality noted in its stock price, with June historically showing the highest probability of positive returns at 63.64%, while April may not be an ideal month for investment with a 27.27% probability of a positive return.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases, particularly those targeting the interleukin-1β (IL-1β) pathway. Their lead asset, abdakibart (AVTX-009), is in Phase 2 clinical trials for hidradenitis suppurativa (HS) and is being explored for other immune-mediated diseases. The company's pipeline also includes quisovalimab and AVTX-008. Avalo Therapeutics was incorporated in 2011 and changed its name from Cerecor Inc. in August 2021.

Avalo Therapeutics, Inc. is headquartered in Rockville, Maryland, United States, with a corporate office in Wayne, Pennsylvania. The company primarily focuses on developing therapies for immune dysregulation within the United States.

Information explicitly detailing Avalo Therapeutics, Inc.'s brand reputation is not readily available. The available information primarily focuses on the company's scientific advancements, clinical trial progress, financial performance, and stock-related news.

Avalo Therapeutics, Inc. is primarily owned by institutional shareholders, who hold 87.26% of the stock. Major institutional owners include Armistice Capital LLC, BVF Inc/il, Nantahala Capital Management, LLC, and Orbimed Advisors Llc. Individual insider owners include Robert Moscato Jr. and Randal Jones. The general public holds about 19% ownership.